{"symbol":"IBM","provider":"yahoo-finance","fetchedAt":"2025-12-26T10:19:19.022Z","asOfDate":"2025-12-26","articles":[{"id":"748752e0-71f4-3e5b-94e1-cf2670783c10","title":"DOE’s ‘Genesis Mission’ Enlists AI to Double U.S. Research Productivity in a Decade","url":"https://finance.yahoo.com/m/748752e0-71f4-3e5b-94e1-cf2670783c10/doe%E2%80%99s-%E2%80%98genesis-mission%E2%80%99.html","publisher":"POWER Magazine","publishedAt":"2025-12-25T14:26:30.000Z","relatedTickers":[],"mainIdea":"DOE’s ‘Genesis Mission’ Enlists AI to Double U.S. Research Productivity in a Decade","summary":"POWER Magazine: DOE’s ‘Genesis Mission’ Enlists AI to Double U.S. Research Productivity in a Decade."},{"id":"c76863b5-c2f1-3dad-b559-bea709196d57","title":"Kyndryl Holdings (KD) Fell Following Weak Bookings","url":"https://finance.yahoo.com/news/kyndryl-holdings-kd-fell-following-123957774.html","publisher":"Insider Monkey","publishedAt":"2025-12-25T12:39:57.000Z","relatedTickers":["KD"],"mainIdea":"Kyndryl Holdings (KD) Fell Following Weak Bookings","summary":"Insider Monkey: Kyndryl Holdings (KD) Fell Following Weak Bookings. Loomis Sayles, an investment management company, released its “Small Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities delivered strong results in the third quarter, mainly driven by easing tariff concerns, a pro-growth budget passed by the U.S. Congress, and anticipation of the Federal Reserve’s further […] Related tickers mentioned: KD."},{"id":"ba84deed-64ec-3f33-af71-2f2215b92274","title":"Agios Pharmaceuticals price target raised to $34 from $32 at BofA","url":"https://finance.yahoo.com/news/agios-pharmaceuticals-price-target-raised-110533493.html","publisher":"TipRanks","publishedAt":"2025-12-25T11:05:33.000Z","relatedTickers":["AGIO"],"mainIdea":"Agios Pharmaceuticals price target raised to $34 from $32 at BofA","summary":"TipRanks: Agios Pharmaceuticals price target raised to $34 from $32 at BofA. BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $34 from $32 and keeps a Buy rating on the shares following FDA approval for mitapivat to make it the only drug approved in both transfusion-dependent and non-transfusion-dependent alpha- or beta- thalassemia. The REMS and black box for hepatocellular injury were in line with the firm’s expectations and BofA doesn’t expect this to impact uptake, the analyst tells investors.Claim 70% Off TipRanks This Holiday SeasonUnlock hedg Related tickers mentioned: AGIO."}]}
